KOOL reported Q3/11 revenues of $5.165M minus cost of revenues of $3.145M with a gross profit of $2.02M; an increase of 8% versus revenues of $4.8M in Q3/11 and $5.9M versus Q2/11. Disposable Q3/11 revenues were $3M. The softness in the US and EU cord blood markets affected sales of AXP® AutoXpress™ (AXP) bag sets in Q3/11, but was offset in part by solid year-over-year growth in revenues from our Res Q™60 BMC System (Res-Q) used in the preparation of cell concentrates from bone marrow aspirate at the point-of-care and sales of BioArchive® System used to store stem cells from cord blood. The AXP disposable order forecast from our distributor GE Healthcare calls for a slight dip in orders during Q4/11 versus Q3/11 due to inventory rebalancing but projects quarterly increases in orders throughout FY12 due to the positive signs of a revival in purchases from end customers. SG&A expenses were $2.15M while R&D logged in at $715K with a total operating expense of $2.86M. The cash balance at the end Q3/11 reflected approximately $4M in net proceeds from an offering of shares and warrants completed in 3/11. Q3/11 backlog was $900K. KOOL reported a net loss of $845K, or $0.06 per share, in Q3/11 versus a net loss of $1.4M, or $0.10 per share, in Q3/10, a reduction of 40%. For the first 9 months of FY11, KOOL reported revenues of $18M compared with revenues of $15.9M in the same period a year ago, an increase of 13%. Disposable revenues in the 1st 9 months of FY11 were $10.8M, a 13% increase over disposable revenues of $9.6M in the same period a year ago. KOOL reported a net loss of $1.4M, or $0.10 per share, compared with a net loss of $5M, or $0.36 per share, in the 1st 9 months of FY10, a reduction of 72%. Shares used in computing per share data were 14.84M.
- KOOL ended 3/31/11 with $13.5M in cash and cash equivalents
Seeking Alpha's Disclosure: Past performance is no guarantee of future results. No recommendation or advice is being given as to whether any investment is suitable for a particular investor. Any views or opinions expressed above may not reflect those of Seeking Alpha as a whole. Seeking Alpha is not a licensed securities dealer, broker or US investment adviser or investment bank. Our analysts are third party authors that include both professional investors and individual investors who may not be licensed or certified by any institute or regulatory body.